Basic Information
Priorix-Tetra
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Regulatory Information
SIN13627P
April 3, 2009
Prescription Only
Therapeutic
SUBCUTANEOUS, INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07BD54
Company Information
Active Ingredients
Strength: ≥ 10³ CCID50/dose
Strength: ≥ 10³·³ PFU/dose
Strength: ≥ 10³ CCID50/dose
Strength: ≥ 10⁴·⁴ CCID50/dose
Detailed Information
Contraindications
**Contraindications** _Priorix-Tetra_ is contraindicated in subjects with known hypersensitivity to neomycin or to any other component of the vaccine (for egg allergy, see _Warnings and Precautions_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). A history of contact dermatitis to neomycin is not a contraindication. _Priorix-Tetra_ is contraindicated in subjects having shown signs of hypersensitivity after previous administration of measles, mumps, rubella and/or varicella vaccines. _Priorix-Tetra_ is contraindicated in pregnant women. Pregnancy should be avoided for one month after vaccination (see _Pregnancy and Lactation_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Priorix-Tetra_ is contraindicated in subjects with severe humoral or cellular (primary or acquired) immunodeficiency, e.g. severe combined immunodeficiency, agammaglobulinemia and AIDS or symptomatic HIV infection or an age-specific CD4+ T-lymphocyte percentage in children below 12 months: CD4+ < 25%; children between 12-35 months: CD4+ < 20%; children between 36-59 months: CD4+ < 15% (see also _Warnings and Precautions_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**Indications** _Priorix-Tetra_ is indicated for active immunisation of subjects from the age of 12 months against measles, mumps, rubella and varicella. (see also _Warnings and Precautions, Pharmacodynamics_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). The use of _Priorix-Tetra_ should be based on official recommendations.